News

Newsmogrifydigital2024-07-15T09:24:04+00:00

FEATURED

CONTENT

Mogrify appoints Dr Jonathan Appleby as Chief Scientific Officer

Mogrify Limited (Mogrify^®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need, announces the appointment of Dr Jonathan Appleby as Chief Scientific Officer.

With decades of industry experience in translating both conventional and advanced therapeutic medicines, Jon will lead advancement of the Company’s therapeutic programs in areas including otology, ophthalmology and diabetes toward and into clinical development.

Latest

NEWS

Mogrify solidifies IP position surrounding core technology and expands platform algorithm to enhance cell conversion

Mark Cavanagh2022-05-09T10:42:22+00:0017th December 2020|

Mogrify appoints Profs. Christine Mummery, Graziella Pellegrini and Giulio Cossu to Scientific Advisory Board

Mark Cavanagh2022-05-09T10:42:31+00:002nd November 2020|

Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance

Mark Cavanagh2022-05-09T10:42:45+00:009th October 2020|

Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Business Weekly Awards 2020

Mark Cavanagh2022-05-09T10:42:56+00:0018th September 2020|

Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board

Mark Cavanagh2022-05-09T10:43:02+00:0022nd July 2020|

Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019

Mark Cavanagh2022-05-09T10:43:59+00:005th December 2019|

Load More Posts

Latest

Resources

VIEW ALL RESOURCES

VIEW ALL MEDIA FEATURES

VIEW ALL EVENTS

Follow Us On

Social Media

Tweets by Mogrify